As illustrated within the pages of the current issue of the Proceedings, the specialty of allergy-immunology encompasses a diversity of conditions ranging from the quotidian occurrence of the common cough to the rarity of hereditary angioedema. This issue commences with three review articles, all of which were originally presented as problem-based learning cases at the 2013 Eastern Allergy Conference. The first review article addresses a common pediatric problem, chronic cough. In an insightful review, Weinberger and Fisher 1 provide a structured approach to evaluating chronic cough and, in doing so, explore the broad differential diagnosis of this disorder. Included in the differential diagnosis of chronic cough is supraesophageal reflux disease, which is the focus of a review article authored by Scott and Simon. 2 They describe supraesophageal reflux disease as a condition that can masquerade as a variety of disorders including rhinitis, laryngitis, postnasal drip, throat clearing, and chronic cough, thereby contributing to its diagnostic challenge.
Also included in the differential diagnosis of chronic cough is asthma, a disease state that is a predominant focus of this issue. In an exclusive online article, Li et al. 3 elegantly examine the pathophysiological role of Toll-like receptor 2 on airway inflammation in an allergic mouse model. Uncontrolled airway inflammation and its potential long-term sequelae are areas of great current interest because it has become increasingly clear that early onset asthma in the child may be an antecedent of irreversible chronic obstructive pulmonary disease in the adult. Asthma is, therefore, being increasingly recognized as a potential underlying cause of chronic obstructive pulmonary disease, a common disease with a significant burden of illness. Consequently, it is important that risk factors for the development of irreversible lung disease be identified. In this issue Panettieri 4 reviews current evidence identifying those individuals at greatest risk for the development of severe persistent disease. Hope exists that therapeutic intervention at an early age may favorably alter the course of childhood asthma. Contributing to this hope is the development of novel asthma pharmacotherapy. Reddy et al. 5 examine how the introduction and use of second-generation inhaled glucocorticoids, long-acting ␤-agonists, combination inhaled glucocorticoid/long-acting ␤-agonist products, and leukotriene receptor antagonists have impacted children with severe asthma. These investigators retrospectively reviewed two cohorts of children with severe asthma referred to the National Jewish Hospital 10 years apart. Although they found that the more recent cohort of children experienced better asthma control, it is only through future studies of long-term outcomes that the question of whether improved pharmacotherapy can prevent the development of irreversible airway obstruction will be answered.
Continuing with the asthma theme, the current issue is further enriched by the inclusion of three articles that focus on specific asthma therapies. Kent et al. 6 report on a double-blind, placebo-controlled, five-way crossover study investigating both the dose-response and the duration of action of a 5-lipoxygenase activating protein inhibitor, GSK2190915, and its ability to inhibit exercise-induced bronchospasm in subjects with asthma. In another double blind, placebo controlled 5-way, crossover study, Berger et al. 7 report on the dose-response of formoterol delivered via pressurized metered-dose inhaler in patients aged 6 to Ͻ12 years of age who were also maintained on inhaled budesonide. Previously published studies have indicated that treatment with budesonide and formoterol in fixed combination for both maintenance and reliever therapy is an advantageous approach to asthma management. Takeyama et al. 8 add to this body of literature, reporting on the efficacy of this therapeutic regimen as well as its effect on eosinophilic airway inflammation.
Eosinophilic airway inflammation is a pathological feature of the majority of asthma phenotypes and is particularly prominent in both allergic bronchopulmonary aspergillosis and in aspirin-exacerbated respiratory disease. This latter form of asthma is associated with a significant burden of illness 9 and a pathogenesis thought to be based not only on an overproduction of eicosanoid lipid mediators but also on defective antiinflammatory regulators. Therapeutic aspirin desensitization has been established to be highly efficacious in this disorder for both upper and lower airway symptoms in patients with aspirin-exacerbated respiratory disease. 10 In this issue, Aksu et al. 11 provide insight into the mechanism of the beneficial effect of aspirin desensitization, focusing particularly on T-cell cytokines and plasma lipoxins. In an exclusive online article, Mou et al. 12 report on factors contributing to the misdiagnosis and delayed diagnosis of allergic bronchopulmonary mycosis.
This issue also addresses the topic of drug hypersensitivity with emphasis on the overdiagnosis of drug allergy when based on patient history alone. In a prospective study, Vezir et al. 13 investigated 198 suspected drug reactions in 175 patients, in an attempt to corroborate the occurrence of a positive clinical history with skin testing and provocation tests. In an accompanying editorial, Stevenson and Kowalski 14 stress the low prevalence of true drug allergy and suggest that there exists a worldwide epidemic of overdiagnosis of drug allergies.
The topic of allergic rhinitis is touched on by two articles in this issue. In an online exclusive article, Aydin et al. 15 report on their investigation to determine the prevalence of allergic sensitivity to ornamental plants in patients with allergic rhinitis and/or asthma. The second article addresses safety issues of intranasal corticosteroid therapy in children. Georges et al. 16 provide reassuring information on the effect of intranasal triamcinolone acetonide on basal hypothalamic-pituitary-adrenal axis function in children with allergic rhinitis.
Topics related to food allergy are the focus of two articles in this issue. Oral food desensitization has been receiving considerable interest both in the scientific literature and in the lay press. 17, 18 Sun et al. 19 report on a meta-analysis of randomized controlled trials of allergen-specific immunotherapy for peanut allergy. Although oral desensitization for peanut allergy looks promising, until additional larger, well-designed and double-blind randomized controlled trials are performed, the standard approach to therapy remains dietary avoidance and the constant, immediate availability of automatic injectable epinephrine. Unfortunately, a significant number of practitioners are deficient in their ability to prevent and treat food-induced allergic reactions. In an attempt to meet the educational needs of these practitioners, Rosen et al. 20 report on the impact and user satisfaction with web-based, food allergy, audiovisual, educational materials.
Adding further diversity to this issue are articles on the topics of hereditary angioedema (HAE) and IgE deficiency. The burden of illness attributable to HAE having been established in other areas of the world, 21, 22 Nordenfelt et al. 23 report on the burden of illness attributable to HAE in Sweden. In an exclusive online article, Magen et al. 24 provide insight regarding disease associations with IgE deficiency. The authors suggest that low serum total IgE may serve as an indicator of immune dysregulation and autoimmunity and may provide a novel predictive marker of susceptibility to chronic rhinosinusitis, recurrent otitis media, and autoimmune diseases.
Because of the significant clinical implications regarding IgE deficiency, the article by Magen et al. 24 is featured in this issue's "For the Patient" section. This segment, found in the back of this issue and also available online, consists of a 1-page synopsis of a selected article, which is written in a readily comprehensible fashion to help patients better understand the content of the full article and its diagnostic and therapeutic implications. It is printed in a format to allow reproduction on the practitioner's letterhead for distribution to patients.
In summary, the collection of articles found within the pages of this issue provides another insight into important allergic and respiratory disorders afflicting patients whom the allergist-immunologist serves. In keeping with the overall mission of the Proceedings, which is to distribute timely information regarding advancements in the knowledge and practice of allergy, asthma, and immunology to clinicians entrusted with the care of patients, it is our hope that the articles found within this issue achieve this goal and will help foster enhanced patient management through efficient workup and optimal therapy for a great diversity of clinical problems. These clinical problems include allergic and respiratory disorders seen in various patient populations, ranging across the full age spectrum from infancy to the elderly and from various regions around the world. The pathophysiological mechanisms of allergic and respiratory disease are elegantly explored, illustrating critical insight into the etiology of these diseases and with the potential for future therapeutic innovations. On behalf of the entire Editorial Board, we hope you will enjoy the diversity of literature offered in this issue of the Proceedings. 
